ALT has been demonstrated to decline in patients with treatment‐related improvement or resolution of histological NASH in studies of obeticholic acid,45 elafibranor46 and liraglutide,23 and also shown to decline in association with liver fat reductions among patients with type 2 diabetes and NAFLD treated with the sodium‐glucose cotransporter 2‐inhibitor empagliflozin.47 While correlated outcomes do not always indicate a causative association, several studies have also observed a predictive association between changes in ALT and subsequent NAFLD/NASH‐related outcomes. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.